Amgen, In A Buy Zone, Unveils Highly Anticipated Novartis-Rivaling Sjogren's Data
Detailed summary
Amgen unveiled test results Wednesday that suggest it could have one of the first immune-modulating treatments for Sjogren's disease. The post Amgen, In A Buy Zone, Unveils Highly…
After several high-profile setbacks among its competitors, Amgen (AMGN) unveiled test results Wednesday that suggest it could have one of the first immune-modulating treatments for Sjogren's disease. In Sjogren's disease, the immune system mistakenly attacks the body's moisture-producing glands. This can lead to dry eyes and mouth, joint and muscle pain, and organ dysfunction. Patients were given infusions of Amgen's…
Opening of the article, excerpted from Investor's Business Daily. To read the rest, open the article on the publisher's site.
MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.investors.com)
